淀粉样变性治疗药物市场
淀粉样变性治疗药物市场：2026年市场规模约为69.6亿美元，2031年市场规模约为104.3亿美元；预测期复合年增长率为8.43%；当前最大市场为北美；增长最快的市场为亚太地区。
市场研究正文
规模、增长、细分、驱动因素与关键问题
当前质量分 100.00，审核状态 accepted。结构化字段已按 RoboInd 内容层级组织。
核心结论
淀粉样变性治疗药物市场：2026年市场规模约为69.6亿美元，2031年市场规模约为104.3亿美元；预测期复合年增长率为8.43%；当前最大市场为北美；增长最快的市场为亚太地区。
市场走势
结构化指标
| 指标 | 年份 | 数值 | 性质 |
|---|---|---|---|
| 复合年增长率 | 2031 | 8.43% | 机构预测 |
| 市场规模 | 2026 | USD 6.96 billion | 机构预测 |
| 市场规模 | 2031 | USD 10.43 billion | 机构预测 |
细分市场份额
市场结构
| 维度 | 细分项 | 年份 | 份额 |
|---|---|---|---|
| amyloidosis_type | AL amyloidosis | 2025 | 42.570% |
| drug_modality | small molecules | 2025 | 52.910% |
| end_user | hospitals | 2025 | 48.420% |
| formulation | tablets | 2025 | 51.470% |
| geography | North America | 2025 | 39.550% |
| route_of_administration | oral products | 2025 | 52.130% |
| therapy_class | TTR stabilizers | 2025 | 38.930% |
关键结论
- amyloidosis_type 维度中，AL amyloidosis 在 2025 年的公开份额为 42.57%。
- drug_modality 维度中，small molecules 在 2025 年的公开份额为 52.91%。
- end_user 维度中，hospitals 在 2025 年的公开份额为 48.42%。
- formulation 维度中，tablets 在 2025 年的公开份额为 51.47%。
- geography 维度中，North America 在 2025 年的公开份额为 39.55%。
- route_of_administration 维度中，oral products 在 2025 年的公开份额为 52.13%。
主要参与者
- Pfizer Inc.
- AstraZeneca PLC
- Takeda Pharmaceutical Company Limited
- Bristol Myers Squibb Company
- Sanofi
增长驱动因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| Rising Disease Awareness and Earlier Diagnosis | +2.000% | Global, led by North America and Western Europe | Medium term (2-4 years) |
| Aging Population and ATTR-CM Identification | +2.100% | Global, with strong relevance in Japan, Western Europe, and North America | Long term (≥ 4 years) |
| Regulatory Approvals of Disease-Modifying Therapies | +2.900% | Global, with early gains in the United States, European Union, Japan, and Brazil | Short term (≤ 2 years) |
| Expansion of Specialized Amyloidosis Care Centers | +0.900% | North America and Western Europe, with spillover to Asia-Pacific | Medium term (2-4 years) |
| AI-Enabled Echocardiography and PYxP Referral Pathways | +1.200% | North America and Western Europe | Medium term (2-4 years) |
| Genotype-Guided Therapy and Companion Diagnostics | +1.000% | North America and the European Union, with early gains in Asia-Pacific | Long term (≥ 4 years) |
市场制约因素
| 因素 | 影响 CAGR | 地区相关性 | 影响周期 |
|---|---|---|---|
| High Treatment and Lifetime Disease-Management Costs | -1.300% | Global; MEA, South America, low-income APAC | Long term |
| Limited Patient Pools for Clinical-Trial Recruitment (new) | -0.700% | Global; Portugal, Brazil, Japan most acute | Long term |
| Payer Prior Authorization and Site-of-Care Fragmentation | -1.000% | North America, Western Europe | Medium term |
| Limited RNAi Manufacturing and Cold-Chain Capacity (new) | -0.800% | Global; APAC, MEA, South America | Medium term |
报告关注的关键问题
What is the projected value of amyloidosis therapeutics by 2031?
The value is projected to reach USD 10.43 billion by 2031, growing from USD 6.96 billion in 2026 at an 8.43% CAGR.
Which amyloidosis type is growing fastest?
ATTR amyloidosis is forecast to grow at 8.89% CAGR through 2031, supported by wider diagnosis and more approved treatment choices.
Which therapy class currently leads revenue?
TTR stabilizers held 38.93% of revenue in 2025, while gene silencers are expected to grow fastest at 9.23% CAGR.
Why is subcutaneous administration gaining use?
Subcutaneous delivery is forecast to grow at 10.94% CAGR as extended-interval therapies can reduce dependence on infusion facilities.
Which region has the fastest forecast growth?
Asia-Pacific is forecast to grow at 12.29% CAGR through 2031, supported by Japans patient base and improving access.
What limits patient access to treatment?
Long-term treatment costs, repeat prior authorization, and uneven specialist availability can delay access even after approval.
市场概览
- 增长最快市场：亚太地区
- 最大市场：北美
- 市场集中度：中等
查看来源：Mordor Intelligence